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Anticancer/cytotoxicAbstract A series of 4-(1-aryl-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzenesul-
fonamide derivatives (1–32) was synthesized and evaluated for its in vitro antimicrobial, antiviral
and cytotoxic activities. Antimicrobial results indicated that compounds (11) and (18) were found
to be the most effective ones. In general, the synthesized compounds were bacteriostatic and fungi-
static in their action. The cytotoxic screening results indicated that the compounds were less active
than the standard drug 5-ﬂuorouracil (5-FU). None of the compounds inhibited viral replication at
subtoxic concentrations. In general, the presence of a pyrimidine ring with electron releasing groups
and an ortho- and para-substituted benzoyl moiety favored antimicrobial activities. The results of
Synthesis, antimicrobial, anticancer, antiviral evaluation and QSAR studies 397QSAR studies demonstrated the importance of topological parameters, valence zero order
molecular connectivity index (0vv) and valence ﬁrst order molecular connectivity index (1vv) in
describing the antimicrobial activity of synthesized compounds.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The growing incidence of microbial resistance to currently
used antibiotics represents a serious medical problem. There-
fore, there is an urgent need to develop new classes of thera-
peutic agents to treat microbial infections. A combinational
therapeutic drug with different mechanisms of action is one
of the methods that are being adopted to treat disorders men-
tioned above. Besides the exploitation of new targets, there is
another approach of merging two or more pharmacophores
into a single molecule. This approach can also reduce un-
wanted side effects. The success of this hybridization approach
has already been applied in developing novel antibacterial and
antimalarial agents to overcome drug resistance (Solomon
et al., 2010).
Cancer has become the second cause of mortality in the
world and the development of potent and speciﬁc anticancer
agents is urgently needed because of the problems like severe
toxicity as well as resistance to the existing drugs (Kamal
et al., 2010). The human immunodeﬁciency virus (HIV) epi-
demic continues to have enormous human health conse-
quences. During 2004, around ﬁve million adults and
children became infected with HIV and by the end of the year;
an estimated 39.4 million people worldwide were living with
HIV/AIDS. Non-nucleoside reverse transcriptase inhibitors
(NNRTIs) have gained a deﬁnitive place in the treatment of
HIV-1 infections. This makes them less likely to interfere with
the normal function of other DNA polymerases and therefore
less toxic for the treatment of HIV-infected patients. In this re-
spect, isatin beta-thiosemicarbazone derivatives were found to
demonstrate a range of antiviral activities (Bal et al., 2005).
Isatin is a natural product found in a number of plants,
possesses antibacterial (Karthikeyan et al., 2010), antifungal
(Nandakumar et al., 2010), anticonvulsant (Sridhar et al.,
2002), anti-inﬂammatory (Matheus et al., 2007), anti-HIV
(Bal et al., 2005) and anticancer (Sabet et al., 2010) activities.
In particular, 1-methylisatin-3-thiosemicarbazone (methisa-
zone) is clinically used as an antiviral agent. Thus isatin is a
biologically validated starting point for the design and synthe-
sis of chemical libraries directed at these targets (Adibi et al.,
2010).
Quantitative structure–activity relationship (QSAR) is a
methodology used to correlate the biological property of mol-
ecules with molecular descriptors derived from chemical struc-
tures. It is a mathematical model of a statistically validated
correlation between the chemical structures and their activity
proﬁle (Kumar et al., 2010)
Prompted by the above facts and in continuation of our ef-
forts in developing novel compounds for treatments of antimi-
crobial, anticancer and antiviral infections (Narang et al.,
2012; Judge et al., 2012) we hereby report the synthesis, antimi-
crobial, cytotoxic and antiviral evaluation and QSAR studies
of 4-(1-aryl-2-oxo-1, 2-dihydro-indol-3-ylideneamino)-N-
substituted benzene sulfonamides.2. Results and discussion
2.1. Chemistry
The synthesis of 4-(1-aryl-2-oxo-1, 2-dihydro-indol-3-ylidenea-
mino)-N-substituted benzenesulfonamides (1–32) was accom-
plished by Scheme 1. The physicochemical characteristics of
the synthesized compounds are presented in Table 1.
The synthesized compounds were characterized by IR and
1H NMR spectroscopy and the results are in accordance with
the assigned molecular structures. IR stretching band ranging
from 1727–1673 cm1 (C‚O str., Ar–C‚O) conﬁrmed the
acylation of isatin. IR stretching band at 1674–1618 cm1
(C‚N str.) conﬁrm the formation of a Schiff’s base. Further,
peak of NH in plane bending at 1582–1488 cm1, O‚S‚O
str. at 1182–1143 cm1 conﬁrmed the presence of sulfonamide
moiety in the synthesized compounds.
In the 1H NMR spectra the signals of the respective protons
of the synthesized compounds were conﬁrmed based on their
chemical shifts, multiplicities and coupling constants. These
spectra showed a singlet at 3.23–3.35 ppm, which corresponds
to the SO2NH protons and multiplet at 6.11–8.74 ppm, which
corresponds to aromatic protons. Speciﬁcally, compounds 1, 9,
13, and 21 showed a singlet at 2.31–2.36 ppm which corre-
sponds to CH3 protons on the isoxazole ring.
Similarly compounds 2, 14, 22, and 29 showed a singlet at
1.40–1.95 ppm which corresponds to COCH3 protons, com-
pounds 6, 11, 26, and 28 showed a singlet at 2.33–3.94 ppm
which corresponds to pyrimidine-OCH3 protons, and com-
pounds 7, 12, 29, and 27 showed a singlet at 1.40–3.32 ppm,
which corresponds to pyridazine-OCH3 protons.
2.2. Antimicrobial activity
The antimicrobial activity of the synthesized compounds was
determined by tube dilution method (Cappucino and Sherman
1999) and the results are given in Table 2. In the case of anti-
microbial activity against Staphylococcus aureus, (32) was
found to be most active (pMICsa = 1.62). (11) and (18)
emerged as most potential candidates against Bacillus subtilis,
Escherichia coli and Candida albicans with a pMIC value of
1.67. Against Aspergillus niger, (18) emerged as an effective
antifungal agent (pMICan = 1.67).
In general, the synthesized compounds were bacteriostatic
and fungistatic, as their minimum bactericidal/fungicidal con-
centration (MFC/MBC) values were 3-fold higher than their
MIC values (a drug is considered to be bacteriostatic/fungi-
static when its MFC and MBC values are 3-fold higher than
its MIC values, Emami et al., 2004).
2.3. Cytotoxic activity
The cytotoxic activity of the synthesized isatin derivatives was
determined against breast cancer (MCF 7) and colon cancer
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Scheme 1 Scheme for the synthesis of 4-(1-aryl-2-oxo-1, 2-dihydro-indol-3-ylideneamino)-N-substituted benzenesulfonamide.
398 M. Kumar et al.(HCT116) cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay (Mosmann,
1983), and the results are presented in Table 3. In general all
the synthesized compounds were less active as compared
to the standard drug 5-ﬂuorouracil (5-FU). Among the
synthesized compounds, 4-[1-(2-chloro-benzoyl)-2-oxo-1,2-
dihydro-indol-3-ylideneamino]-N-(4,6-dimethyl-pyrimidin-2-yl)-
benzenesulfonamide (18) and 4-[1-(4-chloro-benzoyl)-2-oxo-
1,2-dihydro-indol-3-ylideneamino]-N-(5-methyl-isoxazol-3-yl)-
benzenesulfonamide (9) were the most effective compounds
against the MCF 7 and HCT116 cancer cell lines (IC50 = 90
and 35 lg/mL, respectively), which may be taken as lead com-
pounds for the development of novel cytotoxic agents.
2.4. Antiviral activity
The antiviral activity of the synthesized isatin derivatives was
determined against different DNA and RNA viruses. None
of the derivatives were found to be markedly active against fe-
line corona virus and feline herpes virus in CrFK cell cultures,
herpes simplex virus-1 (KOS), herpes simplex virus-2 (G), vac-
cinia virus, vesicular stomatitis virus, herpes simplex virus-1
and TK- KOS ACVr in HEL cell cultures, vesicular stomatitis
virus, Coxsackie virus B4 and respiratory syncytial virus in
HeLa cell cultures and Coxsackie virus B4, parainﬂuenza-3
virus, reovirus-1, Sindbis virus and Punta Toro virus in Vero
cell cultures. The anti-HIV activity of synthesized derivatives
was studied against wild-type HIV-1 (IIIB) and HIV-2
(ROD) strains in MT-4 cell cultures using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method.Anti-HIV screening results clearly indicated that none of
the synthesized compounds exhibited signiﬁcant anti-HIV
activity at subtoxic concentrations. Only compounds 10 and
11 showed marginal anti-Coxsackie virus activity at 45 lg/
ml in both (Vero and HeLa) cell cultures.
2.5. Structure–activity relationship
a. The high antibacterial/antifungal activity of compounds
11 and 18 indicated that the presence of electron donat-
ing methyl group on the pyrimidine ring increases the
antimicrobial activity of synthesized isatin derivatives.
The role of electron releasing groups in enhancing the
antimicrobial activity of isatin derivatives with pyrimi-
dine is supported by a study of Pandeya et al. (1999).
b. The presence of an ortho- and para chloro-substituted
benzoyl moiety increased the antimicrobial activity of
synthesized isatin derivatives, whereas an unsubstituted
benzoyl moiety leads to a decrease in biological activity
which indicates that the presence of a chloro group on
ortho or para position of the benzoylmoietymay be useful
for its binding to the receptor. The role of the electron
withdrawing group in improving antibacterial activity is
supported by the studies of Konda et al. (2011).
c. The cytotoxic activity results indicated that the presence
of electron releasing groups (methyl) may increase the
cytotoxic potential of the synthesized isatin derivatives.
The role of electron releasing groups in improving cyto-
toxic activity is supported by the studies of Yogeeswari
et al. (2005) and Mologni et al. (2010).
Table 1 Physicochemical characteristics of the synthesized isatin derivatives.
Comp. M. pt. (oC) M. Formula M. wt. Rf value % Yield
Training set
1 246–248 C25H20N4O5S 488.12 0.72 85
2 88–90 C23H17N3O5S 447.76 0.70 80
3 252–254 C26H20N5O4S 483.10 0.68 72
4 268–270 C29H19N5O4S 498.53 0.64 76
5 213–215 C24H16N4O4S2 488.54 0.62 82
6 124–126 C27H21N5O4S 511.55 0.70 85
7 208–210 C26H19N5O5S 513.52 0.74 74
8 220–222 C26H18N4O4S 482.15 0.78 68
9 203–205 C25H17ClN4O5S 520.06 0.72 76
10 112–114 C26H18ClN5O4S 531.97 0.72 77
11 180–182 C27H20ClN5O6S 545.09 0.74 88
12 223–225 C26H18ClN5O5S 547.97 0.68 66
13 246–248 C25H17N4O5S 520.06 0.72 70
14 120–122 C23H17ClN3O5S 482.92 0.70 82
15 252–254 C25H16ClN5O4S 517.06 0.68 74
16 268–270 C29H18ClN5O4S 531.08 0.64 62
17 213–215 C24H16ClN4O4S2 523.99 0.62 76
18 124–126 C27H20ClN5O4S 545.09 0.70 82
19 208–210 C26H18ClN5O5S 547.97 0.74 70
20 220–222 C26H18ClN4O4S 517.96 0.78 87
21 108–110 C23H16ClN4O6S 476.08 0.72 58
22 112–114 C21H16N3O6S 438.43 0.64 64
23 100–102 C23H15N5O5S 473.46 0.68 78
24 195–197 C24H17N5O5S 487.49 0.72 84
25 148–150 C22H15N4O5S2 479.51 0.70 76
26 180–182 C25H19N5O5S 501.51 0.74 60
27 223–225 C24H17N5O6S 503.49 0.68 88
28 228–230 C24H16N4O5S 472.47 0.62 66
Test set
29 117–119 C23H17ClN3O5S 481.92 0.64 72
30 120–122 C25H17ClN5O4S 518.95 0.68 64
31 148–150 C24H16ClN4O4S2 523.99 0.70 82
32 228–230 C26H17ClN4O4S 516.96 0.62 70
TLC mobile phase: chloroform.
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2.6. QSAR studies
2.6.1. Development of multi-target QSAR model
In order to identify substituent effect on antimicrobial activity,
we established a quantitative structure–activity relationship
(QSAR) between in vitro antimicrobial activity and descriptors
coding for lipophilic, electronic, steric and topological proper-
ties of the molecules under consideration using the linear free
energy relationship model (LFER) described by Hansch and
Fujita (1964).
Antimicrobial activity data determined as MIC values were
ﬁrst transformed into pMIC values and used as a dependent
variable in the QSAR study. The different molecular descrip-
tors (independent variables) like log of octanol–water partition
coefﬁcient (log P), molar refractivity (MR), Kier’s molecular
connectivity (0v, 0vv, 1v, 1vv, 2v, 2vv) and shape (ja1) topologi-
cal indices, Randic topological index (R), Balaban topological
index (J), Wiener topological index (W), Total energy (Te),
energies of highest occupied molecular orbital (HOMO) and
lowest unoccupied molecular orbital (LUMO), dipole moment
(l) and electronic energy (Ele.E), calculated for synthesized
compounds are presented in Table 4. (Hansch and Fujita,1964; Hansch et al., 1973; Kier and Hall, 1976; Randic 1975,
1993; Balaban 1982; Wiener, 1947).
According to ot-QSAR models, one should use ﬁve differ-
ent equations with different errors to predict the activity of a
new compound against the ﬁve microbial species. The ot-
QSAR models, which are present in the whole literature, be-
come impractical to use when we have to predict each com-
pound results for more than one target.
However, very recently the interest has been increased in
the development of multi-target QSAR (mt-QSAR) models
(Sigroha et al. 2012; Sharma et al. 2012; Kumar et al. 2010).
In opposition to ot-QSAR, the mt-QSAR model is a single
equation that considers the nature of molecular descriptors
which are common and essential for describing the antibacte-
rial and antifungal activities. Based on the facts mentioned
above and in continuation of our research in the ﬁeld of mt-
QSAR (Sigroha et al. 2012; Sharma et al. 2012; Kumar et al.
2010), we have attempted to develop three different types of
mt-QSAR models viz. mt-QSAR model for describing antibac-
terial activity of synthesized compounds against S. aureus,
B. subtilis and E. coli, mt-QSAR model for describing anti-
fungal activity of synthesized compounds against C. albicans
and A. niger as well a common mt-QSAR model for describing
the antimicrobial (overall antibacterial and antifungal) activity
Table 2 Antimicrobial activity of synthesized isatin derivatives.
Comp. Minimum inhibitory concentration (MIC, l mol/ml)
pMICsa pMICbs pMICec pMICca pMICan pMICab pMICaf pMICam
Training set
1 1.29 1.29 1.59 1.59 1.29 1.39 1.44 1.41
2 1.25 1.25 1.55 1.55 1.25 1.35 1.4 1.37
3 1.29 1.29 1.29 1.59 1.59 1.29 1.59 1.41
4 1.30 1.30 1.60 1.60 1.30 1.40 1.45 1.42
5 1.29 1.29 1.59 1.59 1.29 1.39 1.44 1.41
6 1.34 1.34 1.64 1.64 1.34 1.44 1.49 1.46
7 1.31 1.31 1.61 1.61 1.61 1.41 1.61 1.49
8 1.29 1.29 1.59 1.59 1.59 1.39 1.59 1.47
9 1.32 1.32 1.62 1.62 1.62 1.42 1.62 1.50
10 1.33 1.63 1.63 1.63 1.33 1.53 1.48 1.51
11 1.36 1.67 1.67 1.67 1.36 1.57 1.52 1.55
12 1.34 1.34 1.64 1.64 1.34 1.44 1.49 1.46
13 1.32 1.32 1.62 1.62 1.62 1.42 1.62 1.50
14 1.29 1.29 1.59 1.59 1.29 1.39 1.44 1.41
15 1.32 1.32 1.62 1.62 1.62 1.42 1.62 1.50
16 1.33 1.33 1.63 1.63 1.63 1.43 1.63 1.51
17 1.32 1.32 1.62 1.62 1.62 1.42 1.62 1.50
18 1.36 1.67 1.67 1.67 1.67 1.57 1.67 1.61
19 1.34 1.34 1.64 1.64 1.34 1.44 1.49 1.46
20 1.32 1.32 1.62 1.62 1.62 1.42 1.62 1.5
21 1.28 1.28 1.58 1.58 1.58 1.38 1.58 1.46
22 1.24 1.24 1.54 1.54 1.54 1.34 1.54 1.42
23 1.28 1.28 1.58 1.58 1.58 1.38 1.58 1.46
24 1.29 1.29 1.59 1.59 1.29 1.39 1.44 1.41
25 1.28 1.28 1.58 1.58 1.58 1.38 1.58 1.46
26 1.33 1.33 1.63 1.63 1.33 1.43 1.48 1.45
27 1.30 1.30 1.61 1.61 1.30 1.40 1.46 1.42
28 1.28 1.28 1.58 1.58 1.58 1.38 1.58 1.46
Test set
29 1.29 1.59 1.59 1.59 1.29 1.49 1.44 1.47
30 1.32 1.62 1.62 1.62 1.32 1.52 1.47 1.50
31 1.32 1.32 1.62 1.32 1.32 1.42 1.32 1.38
32 1.62 1.32 1.32 1.32 1.32 1.42 1.32 1.38
SD 0.06 0.13 0.06 0.06 0.15 0.06 0.09 0.05
Std 2.61a 2.61a 2.61a 2.64b 2.64b – – –
a Norﬂoxacin.
b Fluconazole.
400 M. Kumar et al.of isatin derivatives against all the above mentioned
microorganisms.
In order to develop mt-QSAR models, initially we calcu-
lated the average antibacterial activity, antifungal activity
and antimicrobial activity values of substituted isatin deriva-
tives (Table 2). In the present study, a training set consisting
of 28 isatin derivatives (1–28) was used for linear regression
model generation and a test set consisting of 4 isatin deriva-
tives (29–32) was used for cross validation of the generated
models. Preliminary analysis was carried out in terms of a cor-
relation analysis. A correlation matrix constructed for antibac-
terial activity is presented in Table 5. The correlations of
different molecular descriptors with antibacterial and anti-
fungal activities are presented in Table 6. The regression mod-
els developed using different molecular descriptors are
reported in Eqs. (1) and (2) together with statistical parameters
of regression. The antibacterial activity of synthesized isatin
derivatives is explained by the topological parameter, valence
zero order molecular connectivity index, 0vv (Eq. (1)).
mt-QSAR model for antibacterial activitypMICab ¼ 0:0370vv þ 0:681 ð1Þ
n ¼ 28 r ¼ 0:838 q2 ¼ 0:639 s ¼ 0:033 F ¼ 61:69
Here and thereafter, n – number of data points, r – correlation
coefﬁcient, q2 – cross validated, r2 obtained by leave one out
method, s – standard error of the estimate and F – Fischer
statistics.
As the coefﬁcient of 0vv in Eq. (1) is positive, the antibacte-
rial activity will increase with an increase in the value of 0vv.
This is clearly evident from Table 4 that compounds 11 and
18 having highest 0vv value (22.73 each) have highest antibac-
terial activity value of 1.57 each (Table 2) respectively. Simi-
larly, compound 3 has low 0vv value 18.95, has minimum
antibacterial activity (1.29). The value of q2 for Eq. (1) is
0.639, which means that it can predict 63.9% of variance of
antibacterial activity.
Topological indices (e.g. 0vv) are numerical quantiﬁer of
molecular topology and are sensitive to bonding pattern, sym-
metry, content of heteroatom as well as degree of complexity
Table 3 Anticancer activity of synthesized isatin derivatives
against HCT 116 and MCF 7 cell linesa.
Comp. IC50 (lg/ml)
HCT 116 MCF 7
1 NA >1000
2 70 400
3 70 400
4 45 300
5 40 400
6 >1000 250
7 120 300
8 50 500
9 35 500
10 150 450
11 50 450
12 120 500
13 280 190
14 400 200
15 500 150
16 300 110
17 200 190
18 210 90
19 210 200
20 480 170
21 70 100
22 400 140
23 110 110
24 260 100
25 200 150
26 120 160
27 210 100
28 500 200
29 70 500
30 – >1000
31 90 450
32 80 500
5-FU 0.67 6
NA – not able to obtain IC50 after three independent tests.
a Data represent mean values of three replicates.
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pends on connectivity of its constituent atoms, topological
descriptors derived from information based upon connectivity
can reveal the role of structural or sub-structural information
of amolecule in estimating biological activity, viz. antimicrobial
activity (Lather andMadan, 2005). The QSARmodel expressed
by Eq. (1) was cross validated by its high q2 values (q2 = 0.639)N
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Figure 1 Structure–activity relationship for antimiobtained by leave one out (LOO)method. The value of q2 great-
er than 0.5 is the basic requirement for qualifying aQSARmodel
to be valid (Golbraikh and Tropsha, 2002).
The predictability of the Eq. (1) is evidenced by the low
residual values observed in Table 7 as well by the plot of pre-
dicted pMICab against observed pMICab (Fig. 2). Further, the
plot of observed pMICab versus residual pMICab (Fig. 3) indi-
cated that there was no systemic error in the development of
linear regression model as the propagation of residuals was ob-
served on both sides of zero (Heravi and Kyani, 2004).
Eq. (2) was developed to predict the antimicrobial activity
of isatin derivatives. The antimicrobial activity of synthesized
isatin derivatives is governed by the topological parameter, va-
lence ﬁrst order molecular connectivity index, 1vv (Eq. (2)).
True predictive power of aQSARmodel is to test their ability
to predict accurately the biological activities of compounds from
an external test set (compounds which were not used for the
model development). The low residual activity values observed
in case of test set (29–32) justify the selection of the multiple lin-
ear regression models expressed by Eqs. (1) and (2). It is impor-
tant to mention here that no statistically signiﬁcant correlation
was observed in the case of antifungal activity (Table 6).
The cross-validation of the model developed for antimicro-
bial activity (Eq. (2)) was also done by leave one out (LOO)
technique (Schaper, 1999). In case Eq. (2) q2 value is less than
0.5, the developed model is then considered invalid. But one
should not forget the recommendations of Golbraikh and
Tropsha (2002) who recently reported that the only way to
estimate the true predictive power of a model is to test their
ability to predict accurately the biological activities of com-
pounds. The predictive ability of developed model was evi-
denced by the low residual values observed in Table 7.
mt-QSAR model for antimicrobial activity
pMICam ¼ 0:0561vv þ 0:762 ð2Þ
n ¼ 28 r ¼ 0:736 q2 ¼ 0:454 s ¼ 0:034 F ¼ 30:90
The coefﬁcient of 1vv is positive, which shows that the antimi-
crobial activity will increase with the increase in value of 1vv of
the synthesized compounds, which can be clearly seen from the
results of antimicrobial activity (Table 2) and values of 1vv are
presented in Table 4.
Generally for QSAR studies, the biological activities of
compounds should span 2–3 orders of magnitude. But in the
present study the range of antibacterial and antifungal activi-
ties of the synthesized compounds is within one order ofidine ring
 electron
sing groups
Enhance antimicrobial,
 anticancer and 
antiviral activity
rease antiviral 
vity against DNA 
 RNA viruses
robial,
crobial activity of synthesized isatin derivatives.
Table 4 Values of selected descriptors used in the regression analysis.
Comp. log P 0vv 1vv ja1 R J Te LUMO HOMO l
1 3.80 19.26 12.12 23.45 16.83 1.11 6066.58 1.43 9.40 5.03
2 2.65 17.73 11.13 21.83 15.28 1.30 5592.84 1.61 9.55 4.89
3 3.59 18.95 12.06 23.56 16.94 1.10 5941.01 1.50 9.45 6.13
4 3.78 19.87 12.48 24.51 17.33 1.10 6096.83 1.48 9.44 6.46
5 4.18 19.22 12.64 22.87 16.44 1.11 5786.82 1.44 9.26 4.35
6 4.02 21.61 13.13 27.31 18.80 1.08 6892.74 1.52 9.47 4.57
7 3.96 20.28 12.60 25.43 17.87 1.04 6416.38 1.24 9.31 3.63
8 3.97 19.08 12.20 23.24 16.94 1.10 5876.24 1.44 9.41 5.94
9 4.32 20.37 12.63 24.68 17.23 1.11 6426.68 1.52 9.50 5.43
10 4.30 20.99 12.99 25.75 17.73 1.10 6456.92 1.53 9.50 6.26
11 4.54 22.73 13.64 28.55 19.20 1.08 7252.83 1.58 9.54 4.56
12 4.48 21.40 13.11 26.67 18.26 1.08 6776.58 1.50 9.31 4.94
13 4.32 20.37 12.63 24.68 17.24 1.12 6426.62 1.46 9.43 5.87
14 3.17 18.85 11.65 23.07 15.69 1.32 5952.87 1.59 9.56 4.39
15 4.11 20.07 12.58 24.79 17.35 1.11 6301.05 1.46 9.46 5.62
16 4.30 20.99 13.00 25.75 17.74 1.11 6456.86 1.46 9.44 5.91
17 4.70 20.33 13.15 24.10 16.85 1.13 6146.85 1.42 9.26 4.19
18 4.54 22.73 13.64 28.55 19.21 1.09 7252.77 1.52 9.48 4.22
19 4.48 21.40 13.11 26.67 18.26 1.08 6776.49 1.45 9.23 7.97
20 4.48 21.40 13.11 26.67 18.26 1.08 6776.58 1.50 9.31 4.94
21 2.75 18.51 11.60 22.71 16.33 1.11 6102.21 1.42 9.38 4.66
22 2.54 18.20 11.55 22.81 16.44 1.10 5976.63 1.49 9.43 5.76
23 2.54 18.20 11.55 22.81 16.44 1.10 5976.63 1.49 9.43 5.76
24 2.73 19.13 11.97 23.77 16.83 1.10 6132.46 1.46 9.42 6.76
25 3.13 18.47 12.12 22.13 15.94 1.12 5822.44 1.43 9.27 4.07
26 2.97 20.87 12.61 26.56 18.30 1.08 6928.37 1.51 9.45 4.92
27 2.91 19.53 12.09 24.68 17.37 1.08 6452.11 1.43 9.31 5.85
28 2.92 18.33 11.69 22.50 16.44 1.10 5911.86 1.44 9.39 5.67
Table 5 Correlation matrix for antibacterial activity of synthesized isatin derivatives.
pMICab log P 0vv 1vv R J LUMO HOMO l
pMICab 1 0.596 0.839 0.785 0.747 0.272 0.221 0.189 0.142
log P 1 0.784 0.884 0.635 0.311 0.041 0.161 0.069
0vv 1 0.954 0.942 0.437 0.136 0.028 0.066
1vv 1 0.869 0.496 0.009 0.147 0.103
R 1 0.633 0.022 0.000 0.017
J 1 0.542 0.429 0.156
LUMO 1 0.671 0.092
HOMO 1 0.009
l 1
402 M. Kumar et al.magnitude. But it is important to note that the predictability of
the QSAR models developed in the present study is evidenced
by their low residual values. This is in accordance with results
suggested by earlier studies (Bajaj et al., 2005), according to
which the reliability of the QSAR model lies in its predictive
ability even though the activity data are in the narrow range.
Further, recent literature reveals that the QSAR has been ap-
plied to describe the relationship between narrow range of bio-
logical activity and physicochemical properties of the
molecules (Narasimhan et al., 2007; Sharma et al., 2006; Ku-
mar et al., 2006). When biological activity data lie in a narrow
range, the presence of minimum standard deviation of the bio-
logical activity justiﬁes its use in QSAR studies (Narasimhan
et al., 2007; Kumar et al., 2007). The minimum standard devi-
ation (Table 2) observed in the antimicrobial activity data jus-
tiﬁes its use in QSAR studies.
It was observed from mt-QSAR models [Eqs. (1), (2)] that
the antibacterial and antimicrobial activity of synthesized isat-in derivatives is governed by the topological parameters va-
lence zero order molecular connectivity indices (0vv) and
valence ﬁrst order molecular connectivity indices (1vv).
3. Experimental
3.1. Chemistry
Starting materials were obtained from commercial sources and
were used without further puriﬁcation. Solvents were dried by
standard procedures. Reaction progress was observed by thin
layer chromatography. Melting points were determined in
open capillary tubes on a Sonar melting point apparatus and
are uncorrected.
1H nuclear magnetic resonance (1H NMR) spectra were
determined by Bruker 500 MHz NMR spectrometer in appro-
priate deuterated solvents and are expressed in parts per mil-
lion (d, ppm) downﬁeld from tetramethylsilane (internal
Table 6 Correlation of molecular descriptors with antimicro-
bial activity of the isatin derivatives.
pMICab pMICaf pMICam
log P 0.596 0.339 0.634
MR 0.774 0.246 0.701
0v 0.795 0.178 0.674
0vv 0.839 0.224 0.733
1v 0.747 0.23 0.671
1vv 0.785 0.291 0.737
2v 0.801 0.216 0.701
2vv 0.753 0.289 0.714
3v 0.767 0.023 0.56
3vv 0.692 0.182 0.605
j1 0.787 0.148 0.649
j2 0.717 0.146 0.598
j3 0.734 0.074 0.567
ja1 0.804 0.173 0.677
ja2 0.752 0.184 0.646
ja3 0.774 0.126 0.627
R 0.747 0.23 0.671
J 0.272 0.36 0.412
W 0.767 0.191 0.661
Te 0.795 0.201 0.687
Ee 0.797 0.191 0.683
Ne 0.796 0.19 0.681
Ip 0.189 0.108 0.071
LUMO 0.221 0.326 0.04
HOMO 0.189 0.108 0.071
l 0.142 0.164 0.203
Table 7 Comparison of observed and predicted antimicrobial
activity of the isatin derivatives.
Comp. pMICab pMICam
Obs. Pre. Res. Obs. Pre. Res.
Training set
1 1.39 1.39 0.00 1.41 1.44 0.03
2 1.35 1.33 0.02 1.37 1.39 0.02
3 1.29 1.38 0.09 1.41 1.44 0.03
4 1.40 1.41 0.01 1.42 1.47 0.05
5 1.39 1.39 0.00 1.41 1.47 0.06
6 1.44 1.48 0.04 1.46 1.50 0.04
7 1.41 1.43 0.02 1.49 1.47 0.02
8 1.39 1.38 0.01 1.47 1.45 0.02
9 1.42 1.43 0.01 1.50 1.47 0.03
10 1.53 1.45 0.08 1.51 1.49 0.02
11 1.57 1.52 0.05 1.55 1.53 0.02
12 1.44 1.47 0.03 1.46 1.50 0.04
13 1.42 1.43 0.01 1.50 1.47 0.03
14 1.39 1.37 0.02 1.41 1.42 0.01
15 1.42 1.42 0.00 1.50 1.47 0.03
16 1.43 1.45 0.02 1.51 1.49 0.02
17 1.42 1.43 0.01 1.5 1.50 0.00
18 1.57 1.52 0.05 1.61 1.53 0.08
19 1.44 1.47 0.03 1.46 1.50 0.04
20 1.42 1.47 0.05 1.50 1.50 0.00
21 1.38 1.36 0.02 1.46 1.42 0.04
22 1.34 1.35 0.01 1.42 1.41 0.01
23 1.38 1.35 0.03 1.46 1.41 0.05
24 1.39 1.38 0.01 1.41 1.44 0.03
25 1.38 1.36 0.02 1.46 1.45 0.01
26 1.43 1.45 0.02 1.45 1.47 0.02
27 1.40 1.40 0.00 1.42 1.44 0.02
28 1.38 1.35 0.03 1.46 1.42 0.04
Test set
29 1.49 1.38 0.11 1.47 1.41 0.06
30 1.52 1.42 0.10 1.50 1.47 0.03
31 1.42 1.43 0.01 1.38 1.50 0.12
32 1.42 1.43 0.01 1.38 1.47 0.09
Observed pMICab
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Figure 2 Plot of predicted pMICab values against observed
pMICab values for the model developed by Eq. (1).
Synthesis, antimicrobial, anticancer, antiviral evaluation and QSAR studies 403standard) NMR data are given as multiplicity (s, singlet; d,
doublet; t, triplet; m, multiplet) and number of protons. IR
spectra were recorded on a Varian Resolutions Pro spectro-
photometer in a KBr disk.
3.2. General procedure for the synthesis of 4-(1-aryl-2-oxo-1, 2-
dihydro-indol-3-ylideneamino)-N-Substituted
benzenesulfonamide (1–32)
Thionyl chloride 32.8 g (0.3 mol) was added to different aro-
matic acids (0.25 mol) in a round bottomed ﬂask. After addi-
tion, the mixture was reﬂuxed for 2 h. The excess of thionyl
chloride was removed by distillation. To the solution of acid
chloride (1 mol) was added 0.1 mol of isatin and the mixture
was reﬂuxed for 1.5 h. Then the reaction mixture was cooled
and the resultant precipitate (N-acyl isatin) was collected,
washed with hexane and recrystallized from ethyl acetate. A
solution of 0.05 mol of different sulfonamides in warm ethanol
was added to the solution of corresponding of N-acyl isatins
(0.05 mol) in the presence of small amount of glacial acetic
acid. The mixture was reﬂuxed for 4–6 h. Then the reaction
mixture was allowed to cool at room temperature and the pre-
cipitate obtained was ﬁltered, dried and recrystallized from
ethanol.
3.2.1. 4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-ylideneamino)-
N-(5-methyl-4,5-dihydro-isoxazol-3-yl)-benzenesulfonamide
(1)
Mp (C) 246–248; Yield – 85%; IR (KBr pellets) cm1 1495
(NH in plane bending, sec. amine), 1683 (C‚O str., Ar–
C‚O), 1650 (C‚N str.), 1157 syn (O‚S‚O str.), 1252 (C–
O–N str., isoxazole), 899 (CH out of plane bending, isoxazole),899–669 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.06–7.87 (14H, m, ArH), 3.35 (1H, s, SO2NH), 2.31 (3H, s,
ArCH3).
Observed pMICab
1.61.51.41.31.2
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Figure 3 Plot of residual pMICab values against observed
pMICab values for the model developed by Eq. (1).
404 M. Kumar et al.3.2.2. N-Acetyl-4-(1-benzoyl-2-oxo-1,2-dihydro-indol-3-
ylideneamino)- benzenesulfonamide (2)
Mp (C) 88–90; Yield – 80%; IR (KBr pellets) cm1 1495 (NH
in plane bending, sec. amine), 1686 (C‚O str., Ar–C‚O),
1646 (C‚N str.), 1156 syn (O‚S‚O str.), 1447 (CH3 bending
vibration, COCH3), 894–669 (CH out of plane bending, in-
dole). 1H NMR (DMSO) d; 7.33–8.71 (13H, m, ArH), 3.32
(1H, s, SO2NH), 1.40 (3H, s, COCH3).
3.2.3. 4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-ylideneamino)-
N-pyrimidin-2-yl-benzenesulfonamide (3)
Mp (C) 252–254;Yield – 72%; IR (KBr pellets) cm1 1495 (NH
in plane bending, sec. amine), 1682 (C‚O str., Ar–C‚O), 1648
(C‚N str.), 1157 syn (O‚S‚O str.), 1608 (C‚N str.,pyrimi-
dine), 768 (CH out of plane bending, 4-sustituted pyrimidine),
900–698 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 7.06–8.52 (16H, m, ArH), 3.35 (1H, s, SO2NH).
3.2.4. 3.2.4.4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-
ylideneamino)-N-(methyl-pyrimidin-2-yl)-benzene sulfonamide
(4)
Mp (C) 268–270; Yield – 76%; IR (KBr pellets) cm1 1494
(NH in plane bending, sec. amine), 1678 (C‚O str., Ar–
C‚O), 1654 (C‚N str), 1156 syn (O‚S‚O str), 1611
(C‚N str.,pyridine), 752–795 (CH out of plane bending, 4-
sustituted pyrimidine), 897–697 (CH out of plane bending, in-
dole). 1H NMR (DMSO) d; 5.93–7.78 (15H, m, ArH), 3.36
(1H, s, SO2NH), 2.49 (3H, s, ArCH3).
3.2.5. 4-(1-Benzoyl-2-oxoindol-3-ylideneamino)-N-(thiazol-2-
yl)-benzenesulfonamide (5)
Mp (C) 213–215; Yield – 82%; IR (KBr pellets) cm1 1494
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1639 (C‚N str), 1151 syn (O‚S‚O str), 1583
(C‚N str., thiazole), 750 (C–S–C str., thiazole), 895 (CH
out of plane bending, thiazole), 895–651 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 7.33–8.71 (15, m,
ArH), 3.35 (1H, s, SO2NH).3.2.6. 3.2.6.4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-
ylideneamino)-N-(4,6-dimethyl-pyrimidin-2-yl)-
benzenesulfonamide (6)
Mp (C) 124–126; Yield – 85%; IR (KBr pellets) cm1
1495 (NH in plane bending, sec. amine), 1687 (C‚O str.,
Ar–C‚O), 1646 (C‚N str), 1156 syn (O‚S‚O str), 1277
(C–O–C str.), 1584 (C‚N str.,pyrimidine), 1609 (C‚C
str.,pyrimidine), 893–669 (CH out of plane bending, indole).
1H NMR (DMSO) d; 7.33–8.70 (14H, m, ArH), 3.35 (1H, s,
SO2NH), 1.58 (6H, s, ArCH3).
3.2.7. 3.2.7.4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-
ylideneamino)-N-(6-methoxy-pyridazin-3-yl)-
benzenesulfonamide (7)
Mp (C) 208–210; Yield – 74%; IR (KBr pellets) cm1 1496
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1646 (C‚N str), 1150 syn (O‚S‚O str), 1286 (C–
O–C str.), 1468 (N–N str., pyridazine), 892–676 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.35–8.08
(15H, m, ArH), 3.35 (1H, s, SO2NH), 1.46 (3H, s, ArOCH3).
3.2.8. 4-(1-Benzoyl-2-oxo-1,2-dihydro-indol-3-ylideneamino)-
N-pyridin-2-yl-benzenesulfonamide (8)
Mp (C) 220–222; Yield – 68%; IR (KBr pellets) cm1 1496
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1645 (C‚N str), 1164 syn (O‚S‚O str), 1583
(C‚N str.,pyridine), 1609 (C‚C str.,pyridine), 894–692 (CH
out of plane bending, indole). 1H NMR (DMSO) d; 7.61–
8.73 (15H, m, ArH), 3.35 (1H, s, SO2NH).
3.2.9. 4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
(9)
Mp (C) 203–205; Yield – 76%; IR (KBr pellets) cm1 1492 (NH
in plane bending, sec. amine), 1686 (C‚O str., Ar–C‚O), 1644
(C‚N str), 1143 syn (O‚S‚O str), 746 (C–Cl str., Ar–Cl), 893
(CH out of plane bending, isoxazole), 893–695 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 6.11–8.66 (13H, m,
ArH), 3.35 (1H, s, SO2NH), 2.35 (3H, s, ArCH3).
3.2.10. 4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(4-methyl-pyrimidin-2-yl)-
benzenesulfonamide (10)
Mp (C) 112–114; Yield – 77%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1680 (C‚O str., Ar–
C‚O), 1643 (C‚N str), 1152 Syn (O‚S‚O str), 715 (C–Cl
str., Ar–Cl), 1628 (C‚N str.,pyrimidine), 760 (CH out of
plane bending, 4-sustituted pyrimidine), 890–663 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.64–8.02
(14H, m, ArH), 3.35 (1H, s, SO2NH), 2.37 (3H, s, ArCH3);
13CNMR(DMSO d6, d ppm):168.41, 166.94, 157.40, 153.40,
138.28, 132.51, 131.29, 130.72, 130.04, 128.43, 113.05.
3.2.11. 3.2.11.4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-(4,6-dimethyl-pyrimidi-2-yl)-
benzenesulfonamide (11)
Mp (C) 180–182; Yield – 88%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1680 (C‚O str., Ar–
C‚O), 1655 (C‚N str), 1176 Syn (O‚S‚O str), 760 (C–Cl
str., Ar–Cl), 1254 (C–O–C str.), 1592 (C‚N str.,pyrimidine),
Synthesis, antimicrobial, anticancer, antiviral evaluation and QSAR studies 405851–681 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 7.49–8.02 (13H, m, ArH), 3.35 (1H, s, SO2NH), 2.33 (6H, s,
ArOCH3);
13C–NMR (DMSO d6, d ppm):116.07, 163.03,
139.08, 136.30, 133.95, 132.68, 128.32, 127.02, and 125.56.
3.2.12. 4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(6-methoxy-pyridazin-3-yl)-
benzenesulfonamide (12)
Mp (C) 220–222; Yield – 66%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1680 (C‚O str., Ar–
C‚O), 1645 (C‚N str), 1177 Syn (O‚S‚O str), 1254 (C–
O–C str.), 1472 (N–N str., pyridazine), 897–669 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.49–8.02
(14H, m, ArH), 3.35 (1H, s, SO2NH), 1.40 (3H, s, ArOCH3).
3.2.13. 4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
(13)
Mp (C) 220–222; Yield – 70%; IR (KBr pellets) cm1 1522 (NH
in plane bending, sec. amine), 1688 (C‚O str., Ar–C‚O), 1637
(C‚N str), 1156 Syn (O‚S‚O str), 742 (C-Cl str., Ar–Cl),
893–646 (CH out of plane bending, isoxazole), 893–676 (CH
out of plane bending, indole). 1H NMR (DMSO) d; 6.11–7.85
(13H, m, ArH), 3.35 (1H, s, SO2NH), 2.36 (3H, s, ArCH3).
3.2.14. N-Acetyl-4-[1-(2-chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-benzene sulfonamide (14)
Mp (C) 220–222; Yield – 82%; IR (KBr pellets) cm1 1572 (NH
in plane bending, sec. amine), 1683 (C‚O str., Ar–C‚O), 1640
(C‚N str), 1172 Syn (O‚S‚O str), 744 (C–Cl str., Ar–Cl),
1376 (CH3 bending vibration, COCH3), 855–680 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.67–7.85 (12H,
m, ArH), 3.35 (1H, s, SO2NH), 1.95 (3H, s, COCH3).
3.2.15. 3.2.15.4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-pyrimidin-2-yl-benzenesulfonamide
(15)
Mp (C) 220–222; Yield – 74%; IR (KBr pellets) cm1 1578
(NH in plane bending, sec. amine), 1684 (C‚O str., Ar–
C‚O), 1651 (C‚N str.), 1151 Syn (O‚S‚O str.), 742 (C–
Cl str., Ar–Cl), (C‚N str.,pyrimidine), 795 (CH out of plane
bending, 4-sustituted pyrimidine), 841–667 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 6.64–8.44 (15H, m,
ArH), 3.35 (1H, s, SO2NH).
3.2.16. 4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(4-methyl-pyrimidin-2-yl)-
benzenesulfonamide (16)
Mp (C) 220–222; Yield – 62%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1688 (C‚O str., Ar–
C‚O), 1628 (C‚N str), 1149 Syn (O‚S‚O str), 743 (C–Cl
str., Ar–Cl), (C‚N str.,pyrimidine), 795 (CH out of plane
bending, 4-sustituted pyrimidine), 888–663 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 6.64–8.26 (14H, m,
ArH), 3.35 (1H, s, SO2NH), 2.37 (3H, s, ArCH3).
3.2.17. 3.2.17.4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-thiazol-2-yl-benzene sulfonamide (17)
Mp (C) 220–222; Yield – 76%; IR (KBr pellets) cm1 1495
(NH in plane bending, sec. amine), 1686 (C‚O str., Ar–C‚O), 1629 (C‚N str), 1174 Syn (O‚S‚O str), 743 (C–Cl
str., Ar–Cl), 1592 (C‚N str., thiazole), 743 (C-S-C str., thia-
zole), 855 (CH out of plane bending, thiazole), 855–680 (CH
out of plane bending, indole). 1H NMR (DMSO) d; 6.66–
7.85 (14, m, ArH), 3.35 (1H, s, SO2NH).
3.2.18. 4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(4,6-dimethyl-pyrimidin-2-yl)-
benzenesulfonamide (18)
Mp (C) 124–126; Yield – 82%; IR (KBr pellets) cm1 1536
(NH in plane bending, sec. amine), 1684 (C‚O str., Ar–
C‚O), 1621 (C‚N str), 1145 Syn (O‚S‚O str), 749 (C–Cl
str., Ar–Cl), 1284 (C–O–C str.), 1592 (C‚N str.,pyrimidine),
833–671 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.65–7.83 (13H, m, ArH), 3.94 (1H, s, SO2NH), 3.35 (6H, s,
ArCH3);
13C-NMR (DMSO d6, d ppm):167.53, 160.91, 153.06,
153.00, 152.61, 133.94, 133.47, 132.69, 132.11, 130.49, 129.69,
128.25, 127.85, 126.48, 125.79, 124.17, 122.06.
3.2.19. 4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(6-methoxy-pyridazin-3-yl)-
benzenesulfonamide (19)
Mp (C) 220–222; Yield – 70%; IR (KBr pellets) cm1 1488
(NH in plane bending, sec. amine), 1665 (C‚O str., Ar–
C‚O), 1621 (C‚N str), 1309 anti, 1145 Syn (O‚S‚O str),
1283 (C–O–C str.), 1470 (N–N str., pyridazine), 841–671
(CH out of plane bending, indole). 1H NMR (DMSO) d;
6.65–7.85 (14H, m, ArH), 3.33 (1H, s, SO2NH), 3.32 (3H, s,
ArOCH3).
3.2.20. 3.2.20.4-[1-(2-Chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-pyridin-2-yl-benzene sulfonamide (20)
Mp (C) 220–222; Yield –87%; IR (KBr pellets) cm1 1476
(NH in plane bending, sec. amine), 1688 (C‚O str., Ar–
C‚O), 1635 (C‚N str), 1167 Syn (O‚S‚O str), 744 (C–Cl
str., Ar–Cl), 1582 (C‚N str.,pyridine), 870–679 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.63–8.05
(16H, m, ArH), 3.35 (1H, s, SO2NH).
3.2.21. 4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
(21)
Mp (C) 220–222; Yield – 58%; IR (KBr pellets) cm1 1483
(NH in plane bending, sec. amine), 1688 (C‚O str., Ar–
C‚O), 1652 (C‚N str.), 1162 Syn (O‚S‚O str.), 1070
(C–O srt., furan), 1249 (–C–O–N str., isoxazole), 882–677
(CH out of plane bending, isoxazole), 882–677 (CH out of
plane bending, indole). 1H NMR (DMSO) d;
6.71–8.73 (12H, m, ArH), 3.35 (1H, s, SO2NH), 2.35 (3H, s,
ArCH3).
3.2.22. N-Acetyl-4-[1-(furan-2-carbonyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-benzene sulfonamide (22)
Mp (C) 220–222; Yield – 64%; IR (KBr pellets) cm1
1483 (NH in plane bending, sec. amine), 1724 (C‚O str.,
Ar–C‚O), 1657 (C‚N str.), 1160 Syn (O‚S‚O str.), 1069
(C–O srt., furan), 1450 (CH3 bending vibration, COCH3),
901–677 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.71–8.74 (11H, m, ArH), 3.35 (1H, s, SO2NH), 1.43 (3H, s,
COCH3).
406 M. Kumar et al.3.2.23. 3.2.23.4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-indol-
3-ylideneamino]-N-pyrimidin-2-yl-benzenesulfonamide (23)
Mp (C) 220–222; Yield – 78%; IR (KBr pellets) cm1 1487
(NH in plane bending, sec. amine), 1727 (C‚O str., Ar–
C‚O), 1654 (C‚N str.), 1153 Syn (O‚S‚O str.), 1072 (C–
O srt., furan), 1608 (C‚N str.,pyrimidine), 752 (CH out of
plane bending, 4-sustituted pyrimidine), 882–679 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.64–8.74
(14H, m, ArH), 3.32 (1H, s, SO2NH).
3.2.24. 4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(4-methyl-pyrimidin-2-yl)-
benzenesulfonamide (24)
Mp (C) 220–222; Yield – 84%; IR (KBr pellets) cm1 1483
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1656 (C‚N str), 1161 Syn (O‚S‚O str), 1070 (C–
O srt., furan), 1608 (C‚N str.,pyridine), 777 (CH out of plane
bending, 4-sustituted pyrimidine), 882–674 (CH out of plane
bending, indole). 1H NMR (DMSO) d; 6.64–8.74 (13H, m,
ArH), 3.35 (1H, s, SO2NH), 1.41 (3H, s, ArCH3).
3.2.25. 3.2.25.4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-thiazol-2-yl-benzene sulfonamide (25)
Mp (C) 220–222; Yield – 76%; IR (KBr pellets) cm1
1496 (NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1644 (C‚N str), 1151 Syn (O‚S‚O str), 1070 (C–O
srt., furan), 1585 (C‚N str., thiazole), 737 (C–S–C str., thia-
zole), 881–709 (CH out of plane bending, indole). 1H NMR
(DMSO) d; 7.31–7.92 (12H, m, ArH), 3.35 (1H, s, SO2NH).
3.2.26. 3.2.26.N-(4,6-Dimethyl-pyrimidin-2-yl)-4-[1-(furan-2-
carbonyl)-2-oxo-1,2-dihydro-indol-3-ylidene amino]-
benzenesulfonamide (26)
Mp (C) 220–222; Yield – 60%; IR (KBr pellets) cm1 1527
(NH in plane bending, sec. amine), 1673 (C‚O str., Ar-
C‚O), 1652 (C‚N str), 1161 Syn (O‚S‚O str), 1243 (C–
O–C str.), 1070 (C-O srt., furan), 1607 (C‚N str.,pyrimidine),
882–667 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.71–8.74 (11H, m, ArH), 3.35 (1H, s, SO2NH), 2.43 (6H, s,
ArCH3).
3.2.27. 4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-(6-methoxy-pyridazin-3-yl)-
benzenesulfonamide (27)
Mp (C) 220–222; Yield – 88%; IR (KBr pellets) cm1 1483
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1674 (C‚N str), 1161 Syn (O‚S‚O str), 1087 (C–
O srt., furan), 1242 (C–O–C str.), 1483 (N–N str., pyridazine),
882–672 (CH out of plane bending, indole). 1H NMR (DMSO)
d; 6.71–8.74 (12H, m, ArH), 3.35 (1H, s, SO2NH), 1.42 (3H, s,
ArOCH3).
3.2.28. 3.2.28.4-[1-(Furan-2-carbonyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-pyridin-2-yl-benzenesulfonamide (28)
Mp (C) 220–222; Yield – 66%; IR (KBr pellets) cm1 1523
(NH in plane bending, sec. amine), 1685 (C‚O str., Ar–
C‚O), 1635 (C‚N str), 1181 Syn (O‚S‚O str), 1074 (C-O
srt., furan), 1582 (C‚N str.,pyridine), 870–679 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 6.63–8.05
(15H, m, ArH), 3.23 (1H, s, SO2NH).3.2.29. N-Acetyl-4-[1-(4-chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-benzene sulfonamide(29)
Mp (C) 220–222; Yield – 72%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1687 (C‚O str., Ar–
C‚O), 1644 (C‚N str), 1162 Syn (O‚S‚O str), 746 (C–Cl
str., Ar–Cl), 1407 (CH3 bending vibration, COCH3), 895–
666 (CH out of plane bending, indole). 1H NMR (DMSO) d;
6.64–8.66 (12H, m, ArH), 3.35 (1H, s, SO2NH), 1.40 (3H, s,
COCH3).
3.2.30. 4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-indol-3-
ylideneamino]-N-pyrimidin-2-yl-benzene sulfonamide (30)
Mp (C) 220–222; Yield – 64%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1680 (C‚O str., Ar–
C‚O), 1648 (C‚N str.), 1177 Syn (O‚S‚O str.), 747 (C–
Cl str., Ar–Cl), 1611 (C‚N str.,pyrimidine), 760 (CH out of
plane bending, 4-sustituted pyrimidine), 896–666 (CH out of
plane bending, indole). 1H NMR (DMSO) d; 7.44–8.02
(15H, m, ArH), 3.35 (1H, s, SO2NH).
3.2.31. 3.2.31.4-[1-(4-Chloro-benzoyl)-2-oxo-1,2-dihydro-
indol-3-ylideneamino]-N-thiazol-2-yl-benzene sulfonamide (31)
Mp (C) 220–222; Yield – 82%; IR (KBr pellets) cm1 1492
(NH in plane bending, sec. amine), 1678 (C‚O str., Ar–
C‚O), 1645 (C‚N str), 1177 Syn (O‚S‚O str), 759 (C–Cl
str., Ar–Cl), 1591 (C‚N str., thiazole), 759 (C–S–C str., thia-
zole), 896–654 (CH out of plane bending, thiazole), 896–667
(CH out of plane bending, indole). 1H NMR (DMSO) d;
7.49–8.02 (14, m, ArH), 3.35 (1H, s, SO2NH).
3.2.32. 4-(1-(4-chlorobenzoyl)-2-oxo-indolin-3-ylideneamino)-
N-(pyridin-2-yl)benzenesulfonamide (32)
Mp (C) 228–230; Yield – 70%; IR (KBr pellets) cm1 1491
(NH in plane bending, sec. amine), 1686 (C‚O str., Ar–
C‚O), 1643 (C‚N str), 1164 Syn (O‚S‚O str), 746 (C–Cl
str., Ar–Cl), 1587 (C‚N str.,pyridine), 1610 (C‚C str.,pyri-
dine), 895–665 (CH out of plane bending, indole). 1H NMR
(DMSO) d; 6.63–8.66 (16H, m, ArH), 3.35 (1H, s, SO2NH);
13CNMR(DMSO d6, d ppm):165.11, 162.99, 153.21, 152.86,
152.77, 147.83, 145.76, 138.63, 138.40, 138.11, 137.67, 136.10,
132.70, 132.45, 130.90,130.24, 129.00, 128.49, 128.28, 126.14,
126.07, 122.85, 116.41, 113.84, 113.55, 112.46, 112.17, 111.84.
3.3. Antimicrobial assay
The antimicrobial activity was performed against Gram-posi-
tive bacteria: S. aureus, B. subtilis, the Gram-negative bacteria
E. coli and two fungal strains: C. albicans and A. niger using
the tube dilution method (Cappucino and Sherman, 1999).
Dilutions of test and standard compounds were prepared in
double strength nutrient broth – I.P. (bacteria) or Sabouraud
dextrose broth – I.P. (fungi) (Annon, 2007). The samples were
incubated at 37 C for 24 h (bacteria), at 25 C for 7 h (A. ni-
ger) and at 37 C for 48 h (C. albicans) and the results were re-
corded in terms of minimum inhibitory concentration (MIC).
3.4. Determination of MBC/MFC
The minimum bactericidal concentration (MBC) and fungi-
cidal concentration (MFC) were determined by subculturing
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MIC determination) on fresh medium. MBC and MFC values
represent the lowest concentration of compound that produces
a 99.9% end point reduction (Rodriguez-Arguelles et al.,
2005).3.5. Antiviral assays
The antiviral assays [except anti-human immunodeﬁciency
virus (HIV) assays] were based on inhibition of virus-induced
cytopathicity in HEL [herpes simplex virus type 1 (HSV-1),
HSV-2 (G), vaccinia virus, and vesicular stomatitis virus], Vero
(parainﬂuenza-3, reovirus-1, Coxsackie B4, and Punta Toro
virus), HeLa (vesicular stomatitis virus, Coxsackie virus B4,
and respiratory syncytial virus), MDCK (inﬂuenza A (H1N1;
H3N2) and B virus) and CrFK (feline corona virus (FIPV)
and feline herpes virus) cell cultures. Conﬂuent cell cultures
in microtiter 96-well plates were inoculated with 100 cell cul-
ture inhibitory dose-50 (CCID50) of virus (1 CCID50 being
the virus dose to infect 50% of the cell cultures) in the presence
of varying concentrations (100, 20, 4 lg/ml) of the test com-
pounds. Viral cytopathicity was recorded as soon as it reached
completion in the control virus-infected cell cultures that were
not treated with the test compounds.
The anti-HIV activity of synthesized derivatives was stud-
ied against wild-type HIV-1 (IIIB) and HIV-2 (ROD) strains
in MT-4 cell cultures using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) method (Pauwels
et al. 1988). Brieﬂy, virus stocks were titrated in MT-4 cells
and expressed as the 50% cell culture infective dose (CCID50).
MT-4 cells were suspended in culture medium at 1 · 105 cells/
ml and infected with HIV at a multiplicity of infection of 0.02.
Immediately after viral infection, 100 ll of the cell suspension
was placed in each well of a ﬂat-bottomed microtiter tray con-
taining various concentrations of test compounds. After 4 days
of incubation at 37 C, the number of viable cells was deter-
mined using the MTT method. Compounds were tested in par-
allel for their cytotoxic effects in uninfected MT-4 cell cultures.3.6. Anticancer (cytotoxic) evaluation
The cytotoxic activity of the synthesized compounds were
determined against breast cancer (MCF 7) and colon cancer
(HCT116) cell lines. Cancer cell lines were purchased from
the American Type Culture Collection (ATCC), Manassas,
VA, USA. All cell lines were cultured in RPMI 1640 (Sigma)
supplemented with 10% heat inactivated fetal bovine serum
(FBS) (PAA Laboratories) and 1% penicillin/streptomycin
(PAA Laboratories). Cultures were maintained in a humidiﬁed
incubator at 37 C in an atmosphere of 5% CO2. Cytotoxicity
of the synthesized compounds at various concentrations was
assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide (MTT) (Sigma) assay, as described by
Mosmann (Mosmann 1983) but with minor modiﬁcation, fol-
lowing 72 h of incubation. Assay plates were read using a spec-
trophotometer at 520 nm. Data generated were used to plot a
dose–response curve of which the concentration of test com-
pounds required to kill 50% of the cell population (IC50)
was determined. Anticancer activity was expressed as the mean
IC50 of three independent experiments.3.7. QSAR studies
The QSAR study was used to ﬁnd out correlation between
antimicrobial activity and physicochemical parameters of syn-
thesized isatin derivatives. The structures of synthesized isatin
derivatives were ﬁrst pre-optimized with the Molecular
Mechanics Force Field (MM+) procedure included in Hyper-
chem (1993) and the resulting geometries were further reﬁned
by means of the semiempirical method PM-3 (parametric
Method-3). We chose a gradient norm limit of 0.01 kcal/A˚
for the geometry optimization. The lowest energy structure
was used for each molecule to calculate physicochemical prop-
erties using TSAR 3.3 software for Windows (TSAR 3D Ver-
sion 3.3, 2000). Furthermore, the regression analysis was
performed using the SPSS software package (SPSS for Win-
dows, 1999). The predictive powers of the equation were vali-
dated by determination of cross-validated r2 (q2) using leave
one out (LOO) cross-validation method (Schaper 1999). The
statistical qualities of the equations were judged by the param-
eters like correlation coefﬁcient (r), standard error of estimate
(s) and variance ratio (F) at speciﬁed degrees of freedom and
some other parameters were employed to conﬁrm their predict-
ability and robustness of the developed models.4. Conclusion
A series of 4-(1-aryl-2-oxo-1,2-dihydro-indol-3-ylideneami-
no)-N-substituted benzenesulfonamide derivatives (1–32)
were synthesized and evaluated for their in vitro antimicro-
bial, antiviral and cytotoxic activities. Antimicrobial study re-
sults indicated that compounds 4-[1-(4-chloro-benzoyl)-2-oxo-1,
2-dihydro-indol-3-ylideneamino]-N-(4,6-dimethy-pyrimidin-
2-yl)-benzenesulfonamide (11) and 4-[1-(2-chloro-benzoyl)-2-
oxo-1,2-dihydro-indol-3-ylideneamino]-N-(4,6-dimethy-pyrim-
idin-2-yl)-benzenesulfonamide (18) were found to be the most
effective antimicrobial agents. The cytotoxic screening results
indicated that the synthesized compounds were less active
than the standard drug 5-ﬂuorouracil (5-FU). The antiviral
screening results indicated that none of the synthesized
compounds markedly inhibited viral replication at subtoxic
concentration. In general, the presence of a pyrimidine ring
with electron releasing groups and an ortho- and para-substi-
tuted benzoyl moiety favored the antimicrobial activities. The
results of QSAR studies demonstrated the importance of
topological parameters, valence zero order molecular connec-
tivity index (0vv) and valence ﬁrst order molecular connectiv-
ity index (1vv) in describing the antimicrobial activity.References
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